Autolus Therapeutics (AUTL) Interest Expenses (2021 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Interest Expenses data on file, last reported at $22.8 million in Q4 2025.

• Quarterly Interest Expenses rose 174.06% year-over-year to $22.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.9 million (up 38.38% YoY) and the FY2025 annual result came in at $248.0 million, up 57.98% from the prior year.
• Interest Expenses eased to $22.8 million in Q4 2025, from $118.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $119.8 million in Q2 2025 to a low of -$30.8 million in Q4 2024.
• A 5-year average of $24.3 million and a median of $5.0 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses jumped 4769.01% — and 2024, when it plunged 202.35%.
• Tracing AUTL's Interest Expenses over 5 years: stood at $71000.0 in 2021, then jumped by 4769.01% to $3.5 million in 2022, then jumped by 771.51% to $30.1 million in 2023, then sank by 202.35% to -$30.8 million in 2024, then jumped by 174.06% to $22.8 million in 2025.
• The last three Interest Expenses figures came in at $22.8 million (Q4 2025), $118.7 million (Q3 2025), and $119.8 million (Q2 2025), per Business Quant data.